Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.

Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Abstract Text:

K Kimura,K Yamada,Y Uzuka,T Maekawa,F Takaku,M Shimoyama,M Ogawa,I Amaki,S Osamura,M Ito,Y Sakai,M Oguro,K Hattori,A Hoshino,Y Hirota,K Ohta,T Nakamura,T Masaoka,I Kimura,M Ichimaru,

A phase I-II study of N4-behenoyl-1-beta-D-arabinofuranosyl-cytosine (BH-AC) was conducted by a cooperative study group. In phase I study, a total of 126 patients, 64 of whom had metastatic solid tumors and 62 of whom had leukemia, were administered BH-AC in a single IV dose at day 1 only or in daily IV doses for 3 to 21 days, with dose ranges of 1.5--10.0 mg/kg. Side effects included nausea and vomiting, which were significantly less in incidence and severity than those observed with ara-C. Myelosuppressive toxicity became severe with doses 3.6--5.0 mg/kg per day x 10 days. In phase II study, a total of 37 adult patients with acute leukemia were entered in the study. Responses were noted, with an overall rate of 35% complete remission. Of th 26 patients with AML, there were 13 CR. The recommended schedule of treatment for BH-AC, based on our data, is daily infusion of 4--5 mg/kg over 3 h for approximately 3 weeks. The results with BH-AC in patients with acute leukemia are superior to those which have been reported for ara-C.

Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Publishing Authors By Initials

K Kimura,K Yamada,Y Uzuka,T Maekawa,F Takaku,M Shimoyama,M Ogawa,I Amaki,S Osamura,M Ito,Y Sakai,M Oguro,K Hattori,A Hoshino,Y Hirota,K Ohta,T Nakamura,T Masaoka,I Kimura,M Ichimaru,

For similar neoplasms research abstracts see: neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 76

Page Numbers: 232-40

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 1981

Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 44671

Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Keywords Mesh Terms:

KEYWORDS: Neoplasms

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Information

Substance Name: enocitabine

Registry Number: 55726-47-1

Grant and Affiliation Information for Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.

AFFILIATION:

Country: GERMANY, WEST

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine Related Publications

• Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.